Drugs / CD1c+ myeloid dendritic cells
CD1c+ myeloid dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02692976 | Sep 2015 → Sep 2017 | prostate neoplasm | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD1c+ myeloid dendritic cells | “vaccination with blood-derived CD1c+ myeloid dendritic cells (mDCs; cDC2) and plasmacytoid DCs (pDCs).” PMID 31727154 ↗ Nov 2019 |
| Known as | cDC2 | “vaccination with blood-derived CD1c+ myeloid dendritic cells (mDCs; cDC2) and plasmacytoid DCs (pDCs).” PMID 31727154 ↗ Nov 2019 |
| Known as | mDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02692976 ↗ |
| Known as | mDCs | “vaccination with blood-derived CD1c+ myeloid dendritic cells (mDCs; cDC2) and plasmacytoid DCs (pDCs).” PMID 31727154 ↗ Nov 2019 |
| Modality | Cell therapy | “cellular-based immunotherapy with dendritic cells (DC).” PMID 33194595 ↗ Oct 2020 |
| Route | Other | “Patients will be vaccinated intranodally three times biweekly with mDC (5x 106 cells; n=7, arm A).” NCT02692976 ↗ |